Compare Gilead Sciences, Inc. (GILD) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Verisign, Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.38 (market cap $163.51B), while Verisign, Inc. trades at $275.27 (market cap $24.62B). The key difference: Gilead Sciences, Inc. is far larger — about 6.6× Verisign, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | VRSN | |
|---|---|---|
Market Cap | $163.51B | $24.62B |
Sector | Health | Technology |
52-Week High | $155.80 | $310.00 |
52-Week Low | $108.22 | $211.49 |
Enterprise Value | $178.05B | $25.86B |
Dividend Yield | 2.49% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VeriSign (VRSN) trades at $268.85, down 0.54% today, with a bullish technical outlook and strong fundamentals. The stock shows consistent revenue growth, reaching $1.66B in 2025, and maintains high profit margins near 50%. Recent Q1 2026 earnings beat expectations at $2.34 EPS, though Q4 2025 missed. Analyst consensus is bullish with a $325.25 price target, and technical indicators suggest support at $265 with resistance at $271.
VRSN offers stable growth driven by its monopoly on .com and .net domains, but faces risks from AI disruption and contract renewals. The stock is fairly valued with a P/E of 29.89, and institutional sentiment is positive. Key risks include high debt levels and competitive threats, yet the company's cash flow and dividend payments support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
